Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Sint-Martens-Latem – page 66

1 432 clinical trials in Sint-Martens-Latem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sint-Martens-Latem at a glance
1 432
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 432 trials in Sint-Martens-Latem

Open in trial search

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with a Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of 19CP02 for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:19Cp02
  • Sponsor:Lakefront Biotherapeutics

IgA nephropathy

Not recruiting

Study on the Effects of Atacicept in Adults with IgA Nephropathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Crohn's disease

Not recruiting

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Study on Langerhans Cell Histiocytosis Treatment in Children and Adolescents Using Cladribine, Prednisolone, and Cytarabine

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Alemtuzumab
  • Sponsor:St. Anna Childrens Cancer Research Institute GmbH

Study on Allogeneic Stem Cell Transplantation for Children and Adolescents with Acute Lymphoblastic Leukemia Using Etoposide, Treosulfan, and Thiotepa

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:St. Anna Childrens Cancer Research Institute GmbH

IgA nephropathy

Not recruiting

Phase 3 Study of Zigakibart (BION-1301) in Adults with IgA Nephropathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Exelixis Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GSKVx000000017064
  • Sponsor:GlaxoSmithKline Biologicals

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Sint-Martens-Latem

What the registry says about research in the country

01 Musculoskeletal Diseases

Clinical research in Sint-Martens-Latem is focused on musculoskeletal diseases, with a strong emphasis on osteoarthritis and related joint pain. The studies are designed to better understand treatment options that may improve comfort and day-to-day function.

  • Knee osteoarthritis
  • Osteoarthritis
  • Testing new approaches to ease joint pain and support mobility

These trials aim to assess whether emerging therapies can offer meaningful relief for people living with chronic joint disease.

02 Nutritional and Metabolic Diseases

Another active area is nutritional and metabolic diseases, especially studies involving overweight and obesity. Research here is exploring whether new treatments can help with weight management while also addressing related health concerns.

  • Overweight or obesity
  • Evaluating therapies that may support healthier body weight
  • Looking at how metabolic treatment options may affect symptoms linked to joint disease

In addition to weight-related outcomes, the research also considers how these approaches may influence overall well-being in people with overlapping conditions.

03 Combined Osteoarthritis and Weight-Related Research

The clinical trial landscape also brings together osteoarthritis and obesity research, reflecting the close connection between excess body weight and knee pain. This combined focus is especially relevant for patients whose symptoms are affected by both joint and metabolic factors.

  • Knee osteoarthritis with overweight or obesity
  • Measuring changes in pain and physical comfort
  • Assessing whether a new therapy can support both symptom relief and weight-related outcomes

These studies aim to generate practical evidence on treatments that may address more than one aspect of the condition at the same time.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.